title: [Intravitreal injection of bevacizumab (Avastin) for retinal angiomatous proliferation].
abstract: METHODS
  An 81-year-old man presented with stage 2 retinal angiomatous proliferation (RAP) as identified by fluorescein angiography and optical coherence tomography (OCT), and was shown to have a visual acuity (VA) of 20/40. One week after an intravitreal injection of bevacizumab (1.25 mg) the VA improved to 20/25, and the OCT showed a reduction of both intraretinal edema and pigment epithelium detachment. Three months after the injection, no ocular complications were observed, VA was 20/20 and the OCT showed an almost normal macular contour.
  
  
  CONCLUSIONS
  Intravitreal injection of bevacizumab may provide another treatment option for patients with RAP.
authors.affiliation: Consorcio Hospital General Universitario de Valencia, Valencia, España. luisamselem@yahoo.es
authors.forename: L
authors.initials: L
authors.lastname: Amselem
authors.forename: M
authors.initials: M
authors.lastname: Díaz-Llopis
authors.forename: E
authors.initials: E
authors.lastname: Cervera
authors.forename: S
authors.initials: S
authors.lastname: García-Delpech
authors.forename: B
authors.initials: B
authors.lastname: Moratal-Peiro
authors.forename: P
authors.initials: P
authors.lastname: Palomares
mesh_terms: D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000473:pathology; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab